Home > Press > Acrongenomics Announces New Validation Data
Abstract:
Nano-JETA(TM) technology offers great advantages compared to the performance of existing Real Time PCR
Acrongenomics, Inc. , a research and development nanobiotechnology company focused in the field of nanomolecular diagnostic applications, is pleased to announce a major milestone in further validating its Nano-JETA(TM) technology platform through an alternative method, Gel Electrophoresis, and the subsequent sequencing of the amplified genes. Nano-JETA(TM) technology offers great advantages compared to the performance of existing Real Time PCR by achieving nucleic acid amplification, detection and quantification in greatly reduced time (2 minutes for detection and quantification) with the option for isothermal (one-temperature) and non-isothermal protocols.
According to the validation data, Nano-JETA(TM) technology for Real Time PCR application generated consistent quantitative results from the 1st up to the 13th cycle. To further validate the specific amplification results, another method was used where all the amplified products were analysed by Gel Electrophoresis and documented by the BIO RAD Gel Doc EQ(TM) system. The results of the Gel Electrophoresis proved that the known number copies of genes of interest were amplified, visualized and detected in all copies range of levels studied (10-10,000,000 number of copies).
The Gel Electrophoresis bands of the genes of interest were isolated and sequenced by an independent laboratory and the results proved the specificity of our technology.
Due to the need for quantification from the 1st cycle, a quantification model was developed successfully where calculation of the number of copies is based on a new mathematical algebraic algorithm. Our model has already been tested against the existing approved software programs giving identical results when repeated six times with the same sets of experiments and using the same samples.
In comparison to the widely used PCR-based nucleic acid diagnostics, Nano-JETA(TM) Real Time PCR does not require special instrumentation. Our method validation generated conclusive evidence that Nano-JETA(TM) Technology offers key competitive advantages over conventional Real Time PCR, including:
Due to its robustness, speed and simplicity, Nano-JETA(TM) Real Time PCR has the potential to provide researchers and clinicians with highly sensitive, efficient and ultra-fast diagnostic assays that can be used in different diagnostic tests.
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
Related News Press |
Possible Futures
Nanotechnology: Flexible biosensors with modular design November 8th, 2024
Exosomes: A potential biomarker and therapeutic target in diabetic cardiomyopathy November 8th, 2024
Turning up the signal November 8th, 2024
Nanofibrous metal oxide semiconductor for sensory face November 8th, 2024
Nanomedicine
Exosomes: A potential biomarker and therapeutic target in diabetic cardiomyopathy November 8th, 2024
Unveiling the power of hot carriers in plasmonic nanostructures August 16th, 2024
Announcements
Nanotechnology: Flexible biosensors with modular design November 8th, 2024
Exosomes: A potential biomarker and therapeutic target in diabetic cardiomyopathy November 8th, 2024
Turning up the signal November 8th, 2024
Nanofibrous metal oxide semiconductor for sensory face November 8th, 2024
The latest news from around the world, FREE | ||
Premium Products | ||
Only the news you want to read!
Learn More |
||
Full-service, expert consulting
Learn More |
||